- $534.87m
- $539.15m
- $204.73m
- 67
- 47
- 32
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | 2.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.71% | ||
| Return on Equity | -10.34% | ||
| Operating Margin | -18.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 71.08 | 98.05 | 122.29 | 148.73 | 204.73 | 238.83 | 279.53 | 23.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 53 surgical and specialized bracing systems.
Directors
- Mark Throdahl CHM (70)
- David Bailey PRE (42)
- Fred Hite CFO (53)
- Gregory Odle EVP (51)
- Daniel Gerritzen VPR (51)
- Terry Schlotterback LED (65)
- David Pelizzon DRC (65)
- Harald Ruf DRC (67)
- Stephen Burns IND (77)
- Bryan Hughes IND (43)
- Marie Infante IND (71)
- Samuel Riccitelli IND (62)
- Kevin Unger IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 30th, 2007
- Public Since
- October 12th, 2017
- No. of Shareholders
- 684
- No. of Employees
- 562
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 24,831,427
- Address
- 2850 Frontier Drive, WARSAW, 46582
- Web
- https://www.orthopediatrics.com/
- Phone
- +1 5742686379
- Contact
- Philip Taylor
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KIDS
Q1 2025 OrthoPediatrics Corp Earnings Call
OrthoPediatrics Corp Annual Shareholders Meeting
OrthoPediatrics Corp Annual Shareholders Meeting
Q2 2025 OrthoPediatrics Corp Earnings Release
Similar to KIDS
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the Orthopediatrics share price?
As of Today at 22:31 UTC, shares in Orthopediatrics are trading at $21.54. This share price information is delayed by 15 minutes.
How has the Orthopediatrics share price performed this year?
Shares in Orthopediatrics last closed at $21.54 and the price had moved by -28.06% over the past 365 days. In terms of relative price strength the Orthopediatrics share price has underperformed the S&P500 Index by -33.59% over the past year.
What are the analyst and broker recommendations for Orthopediatrics?
The overall consensus recommendation for Orthopediatrics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Orthopediatrics dividend yield?
Orthopediatrics does not currently pay a dividend.
Does Orthopediatrics pay a dividend?
Orthopediatrics does not currently pay a dividend.
When does Orthopediatrics next pay dividends?
Orthopediatrics does not currently pay a dividend.
How do I buy Orthopediatrics shares?
To buy shares in Orthopediatrics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orthopediatrics?
As of the previous close price of $21.54, shares in Orthopediatrics had a market capitalisation of $534.87m.
Where are Orthopediatrics shares listed?
Here are the trading details for Orthopediatrics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KIDS
What kind of share is Orthopediatrics?
Based on an overall assessment of its quality, value and momentum Orthopediatrics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orthopediatrics share price forecast for 2025?
The analyst consensus target price for shares in Orthopediatrics is $37.57. That is 74.42% above the last closing price of $21.54.
Analysts covering Orthopediatrics currently have a consensus Earnings Per Share (EPS) forecast of -$1.30 for the next financial year.
Find out moreWhat is the trend in the Orthopediatrics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orthopediatrics. Over the past six months, its share price has underperformed the S&P500 Index by -11.63%.
As of the last closing price of $21.54, shares in Orthopediatrics were trading -17.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orthopediatrics PE Ratio?
The Orthopediatrics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orthopediatrics?
Orthopediatrics' management team is headed by:
- Mark Throdahl - CHM
- David Bailey - PRE
- Fred Hite - CFO
- Gregory Odle - EVP
- Daniel Gerritzen - VPR
- Terry Schlotterback - LED
- David Pelizzon - DRC
- Harald Ruf - DRC
- Stephen Burns - IND
- Bryan Hughes - IND
- Marie Infante - IND
- Samuel Riccitelli - IND
- Kevin Unger - IND